News Releases

Filter News Releases by year:
2024 | 2023 | 2022 | 2021 | 2020

9 Results

March 2024

New Antibodies Target “Dark Side” of Influenza Virus Protein

March 1, 2024

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored “dark side” of the neuraminidase (NA) protein head. The antibodies target a region of the NA protein that is common among many influenza viruses, including H3N2 subtype viruses, and could be a new target for countermeasures. The research, led by scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center, part of NIH, was published today in Immunity.

September 2023

NIH Clinical Trial of Universal Flu Vaccine Candidate Begins

September 15, 2023

Enrollment in a Phase 1 trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland. The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and will evaluate the investigational vaccine for safety and its ability to elicit an immune response.

May 2023

Clinical Trial of mRNA Universal Influenza Vaccine Candidate Begins

May 15, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health, has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase 1 trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.

January 2023

Developing Mucosal Vaccines for Respiratory Viruses

January 11, 2023

Vaccines that provide long-lasting protection against influenza, coronaviruses and respiratory syncytial virus (RSV) have proved exceptionally difficult to develop. In a new review article in Cell Host & Microbe, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, explore the challenges and outline approaches to improved vaccines. Anthony S. Fauci, M.D., former NIAID director, is an author along with Jeffery K. Taubenberger, M.D., Ph.D., and David M. Morens, M.D.

June 2022

Trial of Potential Universal Flu Vaccine Opens at NIH Clinical Center

June 28, 2022

A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland. The placebo-controlled trial will test the safety of a candidate vaccine, BPL-1357, and its ability to prompt immune responses. The vaccine candidate was developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID). The single-site trial can enroll up to 100 people aged 18 to 55 years and is led by NIAID investigator Matthew J. Memoli, M.D.

February 2022

Leadership Transition at the NIAID Vaccine Research Center

February 16, 2022

I extend my heartfelt gratitude and deepest respect to John R. Mascola, M.D., as he announces his retirement as Director of the Dale and Betty Bumpers Vaccine Research Center at the National Institute of Allergy and Infectious Diseases. Dr. Mascola will leave NIAID at the end of March.

June 2021

NIH Launches Clinical Trial of Universal Influenza Vaccine Candidate

June 1, 2021

A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. Healthy participants 18 to 50 years old will receive either a licensed seasonal influenza vaccine or the experimental vaccine, FluMos-v1.

April 2021

NIAID Funds New Influenza Research Network

April 14, 2021

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has established a network of research sites to study the natural history, transmission and pathogenesis of influenza and provide an international research infrastructure to address influenza outbreaks.

February 2021

Intranasal Influenza Vaccine Spurs Strong Immune Response in Phase 1 Study

February 3, 2021

An experimental influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study, NIH reports.